Nan Shan Life Insurance Co. Ltd. Sells 492,590 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Nan Shan Life Insurance Co. Ltd. trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 66.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 243,792 shares of the biopharmaceutical company's stock after selling 492,590 shares during the quarter. Nan Shan Life Insurance Co. Ltd.'s holdings in Gilead Sciences were worth $22,519,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC raised its holdings in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after acquiring an additional 1,058,331 shares during the period. Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after buying an additional 749,047 shares during the period. Norges Bank bought a new stake in Gilead Sciences during the fourth quarter worth about $1,789,254,000. Finally, Northern Trust Corp boosted its stake in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the sale, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. The trade was a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 25,429 shares of company stock worth $2,894,445. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on GILD shares. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 25th. Royal Bank of Canada upped their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Bank of America lifted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Finally, Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Stock Up 2.7%

Shares of NASDAQ:GILD traded up $2.75 during mid-day trading on Monday, reaching $105.25. 3,183,231 shares of the stock were exchanged, compared to its average volume of 7,660,236. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock's 50 day simple moving average is $105.75 and its 200-day simple moving average is $99.84. The company has a market cap of $130.93 billion, a P/E ratio of 284.36, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.